Publication
Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin
dc.contributor.author | Brasileiro, A | |
dc.contributor.author | Fonseca Oliveira, J | |
dc.contributor.author | Pinheiro, S | |
dc.contributor.author | Paiva-Lopes, MJ | |
dc.date.accessioned | 2018-01-15T16:28:21Z | |
dc.date.available | 2018-01-15T16:28:21Z | |
dc.date.issued | 2016-05 | |
dc.description.abstract | The therapeutic efficacy of high-dose intravenous immunoglobulin in systemic lupus erythematosus (SLE) patients is well established. However, side effects might limit its use and lead to the consideration of therapeutic alternatives, such as the subcutaneous formulation of immunoglobulin, which has been used in some patients with other autoimmune diseases. We report a case of SLE refractory to classical therapies. High-dose intravenous immunoglobulin was effective, but gave rise to significant side effects. The patient was successfully treated with subcutaneous human immunoglobulin, achieving and maintaining clinical and laboratory remission. A lower immunoglobulin dose was needed and no side effects were observed, compared to the intravenous administration. Subcutaneous immunoglobulin could be a better-tolerated and cost-saving therapeutic option for select SLE patients. | pt_PT |
dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
dc.identifier.citation | Lupus. 2016 May;25(6):663-5. | pt_PT |
dc.identifier.doi | 10.1177/0961203316630116 | pt_PT |
dc.identifier.uri | http://hdl.handle.net/10400.17/2847 | |
dc.language.iso | eng | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | SAGE Publications | pt_PT |
dc.subject | Dose-Response Relationship, Drug | pt_PT |
dc.subject | Female | pt_PT |
dc.subject | Humans | pt_PT |
dc.subject | Immunoglobulins | pt_PT |
dc.subject | Immunoglobulins, Intravenous | pt_PT |
dc.subject | Immunologic Factors | pt_PT |
dc.subject | Injections, Subcutaneous | pt_PT |
dc.subject | Lupus Erythematosus, Systemic | pt_PT |
dc.subject | Middle Aged | pt_PT |
dc.subject | Treatment Outcome | pt_PT |
dc.subject | HSAC DER | pt_PT |
dc.subject | HSAC MED | pt_PT |
dc.title | Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.endPage | 665 | pt_PT |
oaire.citation.issue | 6 | pt_PT |
oaire.citation.startPage | 663 | pt_PT |
oaire.citation.title | Lupus | pt_PT |
oaire.citation.volume | 25 | pt_PT |
rcaap.rights | openAccess | pt_PT |
rcaap.type | article | pt_PT |